Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts-Reference-Cited by-同舟云学术

Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts

Published:2014-12 Issue:6 Volume:16 Page:
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Humphreys Jennifer H,van Nies Jessica AB,Chipping Jackie,Marshall Tarnya,van der Helm-van Mil Annette HM,Symmons Deborah PM,Verstappen Suzanne MM

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1186/s13075-014-0483-3.pdf

Reference30 articles.

1. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, Fraser A, Emery P: Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology. 2006, 45: 478-480. 10.1093/rheumatology/kei203.

2. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys EM, De Keyser F: Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004, 63: 1587-1593. 10.1136/ard.2003.017574.

3. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF: Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis. 2005, 64: 1744-1749. 10.1136/ard.2004.033571.

4. Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, Harada Y, Katada Y, Ikeue H, Umeshita-Sasai M, Miyatake K, Saeki Y: Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol. 2007, 26: 1627-1633. 10.1007/s10067-007-0558-5.

5. Bos WH, Bartelds GM, Vis M, van der Horst AR, Wolbink GJ, Van De Stadt RJ, Van Schaardenburg D, Dijkmans BA, Lems WF, Nurmohamed MT, Aarden L, Hamann D: Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. Ann Rheum Dis. 2009, 68: 558-563. 10.1136/ard.2008.088401.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redefining seropositive rheumatoid arthritis: Clinical implications of anti-carbamylated protein on remission, radiographic damage and quality of life;Annals of the Academy of Medicine, Singapore;2024-01-30

2. Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort;Annals of the Rheumatic Diseases;2023-11-18

3. Role of Inflammatory Cytokines in Rheumatoid Arthritis and Development of Atherosclerosis: A Review;Medicina;2023-08-26

4. Different Clinical Relevance of Anti-Citrullinated Protein Antibodies in RA Patients;Doklady Biochemistry and Biophysics;2023-08

5. Should ACR/EULAR criteria be revised changing the RF and ACPA scores?;Autoimmunity Reviews;2023-08